Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | KRAS | P01116 | 6/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.34 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050790 | 0.86 | KRAS (0.39) | KRAS | |
| SCHEMBL21136846 | 0.85 | KRAS (0.51) | HDAC6KRASHDAC8USP30GPR119 | |
| SCHEMBL21099582 | 0.85 | KRAS (0.51) | HDAC6KRASHDAC8USP30GPR119 | |
| SCHEMBL21099999 | 0.85 | KRAS (0.51) | HDAC6KRASHDAC8USP30GPR119 | |
| SCHEMBL21099608 | 0.82 | KRAS (0.59) | HDAC6KRASSMARCA2SMARCA4PBRM1 | |
| SCHEMBL21099612 | 0.78 | KRAS (0.50) | HDAC6KRASHDAC8SMARCA2SMARCA4 | |
| SCHEMBL21099365 | 0.77 | KRAS (0.49) | HDAC6KRASHDAC8GPR119IDO1 | |
| SCHEMBL23512857 | 0.76 | USP30 (0.39) | HDAC6KRASUSP30SMARCA2SMARCA4 | |
| SCHEMBL23512534 | 0.76 | USP30 (0.39) | HDAC6KRASUSP30SMARCA2SMARCA4 | |
| SCHEMBL29693184 | 0.76 | USP30 (0.39) | HDAC6KRASUSP30SMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | HDAC6 1708/4885KRAS 272/4885HDAC8 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.